ERNA

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Eterna Therapeutics Inc

NASDAQ | ERNA

1.76

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 29, 2025)

$9.59M

Market Cap

-

P/E Ratio

-17.76

EPS

$18.00

52 Week High

$1.09

52 Week Low

HEALTHCARE

Sector

ERNA Chart

Recent Chart
Price Action

ERNA Technicals

Tags:

ERNA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $486K
Total Revenue $582K
Cost Of Revenue $96K
Costof Goods And Services Sold $96K
Operating Income -$16M
Selling General And Administrative $13M
Research And Development $4.6M
Operating Expenses $16M
Investment Income Net -
Net Interest Income -$6.5M
Interest Income $249K
Interest Expense $6.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.6M
Income Before Tax -$45M
Income Tax Expense $30K
Interest And Debt Expense -
Net Income From Continuing Operations -$45M
Comprehensive Income Net Of Tax -
Ebit -$38M
Ebitda -$36M
Net Income -$45M

Revenue & Profitability

Earnings Performance

ERNA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $5.3M
Total Current Assets $2.4M
Cash And Cash Equivalents At Carrying Value $1.7M
Cash And Short Term Investments $1.7M
Inventory -
Current Net Receivables $437K
Total Non Current Assets $2.9M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill $2M
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $186K
Other Non Current Assets -
Total Liabilities $3.6M
Total Current Liabilities $2.9M
Current Accounts Payable $1.7M
Deferred Revenue -
Current Debt -
Short Term Debt $207K
Total Non Current Liabilities $630K
Capital Lease Obligations $684K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $684K
Other Current Liabilities $1M
Other Non Current Liabilities $152K
Total Shareholder Equity $1.7M
Treasury Stock -
Retained Earnings -$232M
Common Stock $257K
Common Stock Shares Outstanding $28M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$16M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.6M
Capital Expenditures $369K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$365K
Cashflow From Financing $6.3M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout $16K
Dividend Payout Common Stock $16K
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$45M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $486K
Total Revenue $582K
Cost Of Revenue $96K
Costof Goods And Services Sold $96K
Operating Income -$16M
Selling General And Administrative $13M
Research And Development $4.6M
Operating Expenses $16M
Investment Income Net -
Net Interest Income -$6.5M
Interest Income $249K
Interest Expense $6.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.6M
Income Before Tax -$45M
Income Tax Expense $30K
Interest And Debt Expense -
Net Income From Continuing Operations -$45M
Comprehensive Income Net Of Tax -
Ebit -$38M
Ebitda -$36M
Net Income -$45M

ERNA News

ERNA Profile

Eterna Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Eterna Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Brooklyn, New York, dedicated to advancing innovative immunotherapy solutions to address critical unmet needs in cancer treatment. By harnessing cutting-edge technology platforms, Eterna aims to redefine the therapeutic landscape and improve patient outcomes in oncology. With a robust commitment to research and strategic collaborations, Eterna is positioned to deliver significant advancements and value within the biopharmaceutical sector, making it an attractive prospect for institutional investors.

CMBM
+377.34%
$2.95
PPBT
+81.81%
$1.06
NVDA
+2.98%
$207.04
GPUS
-18.57%
$0.44
BYND
-6.58%
$1.84
ERNA
+40.79%
$1.76
NOK
-5.66%
$7.33
ASST
-13.19%
$1.25
PFSA
-1.31%
$0.28
PLUG
-1.07%
$2.76
F
+0.83%
$13.24
DNN
+3.25%
$3.17
YDKG
-10.75%
$0.05
INTC
-0.45%
$41.34
MSAI
+19.37%
$1.01
FI
-44.04%
$70.59
T
-2.17%
$25.14
SOFI
-2.40%
$30.90
BURU
-7.53%
$0.34
WULF
-9.03%
$14.50
BBD
+3.83%
$3.52
ABEV
-1.35%
$2.18
VSEE
+30.18%
$1.38
FUBO
+1.64%
$3.70
WTO
-12.92%
$0.04
TLIH
+17.97%
$0.50
TSLA
+0.20%
$461.51
AXDX
-61.36%
$0.03
VHAI
+33.33%
$0.00
PFE
-0.85%
$24.29
BITF
-0.93%
$4.26
PLTR
+4.85%
$198.81
DVLT
-17.33%
$2.67
RIG
+2.13%
$3.83
RGTI
+6.31%
$39.40
KVUE
-1.37%
$14.31
CJET
-39.88%
$0.06
LUMN
+9.45%
$11.00
TLRY
-1.44%
$1.36
YYGH
+18.51%
$0.35
BTG
-2.65%
$4.76
JOBY
+9.09%
$17.03
GRAB
+1.85%
$6.05
QS
+1.60%
$15.84
VZ
+2.26%
$40.21
NAKA
+3.13%
$0.94
KDLY
+3.13%
$0.94
ACHR
+0.35%
$11.18
ADAP
-15.14%
$0.05
AMZN
+0.45%
$230.30
CAN
-5.51%
$1.37
HBAN
-2.44%
$15.16
AMD
+2.44%
$264.33
AAPL
+0.26%
$269.70
VALE
+1.80%
$11.83
ETHD
+6.44%
$3.80
QBTS
+7.06%
$34.26
AAL
+2.04%
$12.97
KHC
-4.46%
$24.38
RXRX
-0.67%
$5.87
NIO
+0.70%
$7.14
NGD
+10.58%
$7.00
RMBL
+60.50%
$3.21
GOOGL
+2.65%
$274.57
AMCR
-4.19%
$8.00
BTBT
+1.06%
$3.80
ADD
-25.47%
$0.05
PYPL
-4.57%
$69.68
JAMF
+15.24%
$12.85
QUBT
+4.09%
$15.52
IONZ
-13.97%
$3.57
GGB
+4.04%
$3.60
SNAP
0.00%
$7.74
ONDS
-0.58%
$6.75
AVTR
-23.20%
$11.58
HPE
+0.08%
$24.27
SRM
+53.27%
$10.30
RIVN
+1.55%
$13.71
MARA
0.00%
$18.88
CLSK
-1.35%
$18.89
RF
-0.82%
$24.07
WBD
+1.66%
$21.34
CIFR
-1.85%
$19.59
MSFT
-0.09%
$541.54
RR
-3.61%
$5.07
CCL
+0.03%
$27.87
PLTD
-4.80%
$6.14
AMC
-2.20%
$2.66
ERIC
+3.48%
$10.10
SOUN
+2.48%
$18.14
UPS
+8.00%
$96.36
NVTS
+5.76%
$13.57
QH
-84.48%
$1.26
VRNS
-48.66%
$32.34
KDP
-5.89%
$27.15
BAC
-0.54%
$52.58
APLD
+0.26%
$34.42
AGNC
-1.27%
$10.06
WLGS
-5.57%
$0.04
BMNR
-5.29%
$49.76
CMBM
+377.34%
$2.95
PPBT
+81.81%
$1.06
NVDA
+2.98%
$207.04
GPUS
-18.57%
$0.44
BYND
-6.58%
$1.84
ERNA
+40.79%
$1.76
NOK
-5.66%
$7.33
ASST
-13.19%
$1.25
PFSA
-1.31%
$0.28
PLUG
-1.07%
$2.76
F
+0.83%
$13.24
DNN
+3.25%
$3.17
YDKG
-10.75%
$0.05
INTC
-0.45%
$41.34
MSAI
+19.37%
$1.01
FI
-44.04%
$70.59
T
-2.17%
$25.14
SOFI
-2.40%
$30.90
BURU
-7.53%
$0.34
WULF
-9.03%
$14.50
BBD
+3.83%
$3.52
ABEV
-1.35%
$2.18
VSEE
+30.18%
$1.38
FUBO
+1.64%
$3.70
WTO
-12.92%
$0.04
TLIH
+17.97%
$0.50
TSLA
+0.20%
$461.51
AXDX
-61.36%
$0.03
VHAI
+33.33%
$0.00
PFE
-0.85%
$24.29
BITF
-0.93%
$4.26
PLTR
+4.85%
$198.81
DVLT
-17.33%
$2.67
RIG
+2.13%
$3.83
RGTI
+6.31%
$39.40
KVUE
-1.37%
$14.31
CJET
-39.88%
$0.06
LUMN
+9.45%
$11.00
TLRY
-1.44%
$1.36
YYGH
+18.51%
$0.35
BTG
-2.65%
$4.76
JOBY
+9.09%
$17.03
GRAB
+1.85%
$6.05
QS
+1.60%
$15.84
VZ
+2.26%
$40.21
NAKA
+3.13%
$0.94
KDLY
+3.13%
$0.94
ACHR
+0.35%
$11.18
ADAP
-15.14%
$0.05
AMZN
+0.45%
$230.30
CAN
-5.51%
$1.37
HBAN
-2.44%
$15.16
AMD
+2.44%
$264.33
AAPL
+0.26%
$269.70
VALE
+1.80%
$11.83
ETHD
+6.44%
$3.80
QBTS
+7.06%
$34.26
AAL
+2.04%
$12.97
KHC
-4.46%
$24.38
RXRX
-0.67%
$5.87
NIO
+0.70%
$7.14
NGD
+10.58%
$7.00
RMBL
+60.50%
$3.21
GOOGL
+2.65%
$274.57
AMCR
-4.19%
$8.00
BTBT
+1.06%
$3.80
ADD
-25.47%
$0.05
PYPL
-4.57%
$69.68
JAMF
+15.24%
$12.85
QUBT
+4.09%
$15.52
IONZ
-13.97%
$3.57
GGB
+4.04%
$3.60
SNAP
0.00%
$7.74
ONDS
-0.58%
$6.75
AVTR
-23.20%
$11.58
HPE
+0.08%
$24.27
SRM
+53.27%
$10.30
RIVN
+1.55%
$13.71
MARA
0.00%
$18.88
CLSK
-1.35%
$18.89
RF
-0.82%
$24.07
WBD
+1.66%
$21.34
CIFR
-1.85%
$19.59
MSFT
-0.09%
$541.54
RR
-3.61%
$5.07
CCL
+0.03%
$27.87
PLTD
-4.80%
$6.14
AMC
-2.20%
$2.66
ERIC
+3.48%
$10.10
SOUN
+2.48%
$18.14
UPS
+8.00%
$96.36
NVTS
+5.76%
$13.57
QH
-84.48%
$1.26
VRNS
-48.66%
$32.34
KDP
-5.89%
$27.15
BAC
-0.54%
$52.58
APLD
+0.26%
$34.42
AGNC
-1.27%
$10.06
WLGS
-5.57%
$0.04
BMNR
-5.29%
$49.76
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.